BioCardia (BCDA) Stock Price, News & Analysis

Company Overview

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.

Key Stats

• Today's Range: $2.51 to $2.66
• 50-Day Range: $2.01 to $2.84
• 52-Week Range: $1.63 to $6.87
• Volume: 45,543 shs
• Average Volume: 275,442 shs
• Market Capitalization: $12.01 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $25.00
• Consensus Rating: Strong Buy

BioCardia Stock Analysis - MarketRank™

BioCardia scored higher than 69% of companies evaluated by MarketBeat, and ranked 297th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Strong Buy

Consensus Rating

BioCardia has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

BioCardia has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for BioCardia are expected to grow in the coming year, from ($3.52) to ($1.22) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BioCardia is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BioCardia is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.54% of the float of BioCardia has been sold short.

Short Interest Ratio / Days to Cover

BioCardia has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BioCardia has recently increased by 4.66%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioCardia does not currently pay a dividend.

Dividend Growth

BioCardia does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.54% of the float of BioCardia has been sold short.

Short Interest Ratio / Days to Cover

BioCardia has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BioCardia has recently increased by 4.66%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.9 / 5
• News Sentiment: 0.98

News Sentiment

BioCardia has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for BioCardia this week, compared to 1 article on an average week.

Search Interest

3 people have searched for BCDA on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added BioCardia to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, BioCardia insiders have bought 830.07% more of their company's stock than they have sold. Specifically, they have bought $60,585.00 in company stock and sold $6,514.00 in company stock.

Percentage Held by Insiders

20.00% of the stock of BioCardia is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 20.57% of the stock of BioCardia is held by institutions.

BCDA Stock Analysis - Frequently Asked Questions

How have BCDA shares performed this year?

BioCardia's stock was trading at $2.18 at the start of the year. Since then, BCDA shares have increased by 20.2% and is now trading at $2.62.
View the best growth stocks for 2025 here.

How were BioCardia's earnings last quarter?

BioCardia, Inc. (NASDAQ:BCDA) announced its earnings results on Tuesday, May, 14th. The company reported ($1.35) earnings per share (EPS) for the quarter. The company earned $0.06 million during the quarter.

When did BioCardia's stock split?

BioCardia's stock reverse split on the morning of Thursday, May 30th 2024. The 1-15 reverse split was announced on Thursday, May 30th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

When did BioCardia IPO?

BioCardia (BCDA) raised $51 million in an initial public offering on the week of July 20th 2015. The company issued 3,900,000 shares at a price of $12.00-$14.00 per share. Cantor Fitzgerald & Co. served as the underwriter for the IPO and Roth Capital Partners and Maxim Group were co-managers.

Who are BioCardia's major shareholders?

BioCardia's top institutional investors include Geode Capital Management LLC (0.68%), CM Management LLC (0.55%) and Concourse Financial Group Securities Inc.. Insiders that own company stock include Peter Altman, Simon H Stertzer, Edward M Gillis and David Mcclung.
View institutional ownership trends.

How do I buy shares of BioCardia?

Shares of BCDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of BioCardia own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BioCardia investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), Predictive Oncology (POAI), Abbott Laboratories (ABT), Ford Motor (F) and Wells Fargo & Company (WFC).

Company Calendar

• Last Earnings: 5/14/2024
• Today: 3/09/2025
• Next Earnings (Estimated): 3/26/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BCDA
• CIK: 925741
• Web: www.biocardia.com
• Phone: (650) 226-0120
• Fax: 310-861-5299
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $25.00
• High Stock Price Target: $25.00
• Low Stock Price Target: $25.00
• Potential Upside/Downside: +854.2%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($4.19)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-11,570,000.00
• Net Margins: -1,999.77%
• Pretax Margin: -10,876.05%
• Return on Equity: N/A
• Return on Assets: -208.38%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.78
• Quick Ratio: 1.78

Sales & Book Value

• Annual Sales: $71,000.00
• Price / Sales: 169.16
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.11) per share
• Price / Book: -2.36

Miscellaneous

• Outstanding Shares: 4,584,000
• Free Float: 3,667,000
• Market Cap: $12.01 million
• Optionable: Optionable
• Beta: 1.28